S-1: NexGel Files S-1 for Stock Resale, Faces Dilution Concerns

NexGel, Inc. has filed an S-1 registration statement to allow selling stockholders to resell up to 15,252,337 shares of common stock, amidst significant risks including potential dilution and a going concern warning.

Summary

• NexGel, Inc. is registering for resale up to 15,252,337 shares of its common stock, primarily issuable upon conversion of convertible promissory notes issued in April and May 2026 financings and an acquisition.
• The company is not selling new shares and will not receive proceeds from this resale; all proceeds go to the selling stockholders.
• A significant risk is the potential for substantial dilution to existing stockholders due to the conversion of these notes, with conversion prices subject to downward adjustments.
• NexGel faces a going concern warning, with only $0.5 million in cash as of June 30, 2026, and a net loss of $4.5 million for the first six months of 2026.
• The company lacks sufficient authorized shares to cover all potential conversions and warrant exercises, and is seeking stockholder approval on September 23, 2026, to increase authorized shares from 25 million to 150 million, a proposal previously rejected.
• The Nasdaq Capital Market symbol for NexGel is NXGL, and the last reported sale price on August 19, 2026, was $0.4040 per share.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's going concern warning, significant dilution risks, and reliance on future stockholder approval for essential share increases.

Positives

• The company has secured financing through convertible notes and warrants in April and May 2026, totaling over $16 million in principal.
• The acquisition of Celularity Inc.'s regenerative biomaterials portfolio under the brand BioNx on April 17, 2026, expands its product offerings.
• Stockholders approved an 'Exchange Cap' waiver at the July 31, 2026 meeting, removing a 19.99% limit on conversions and warrant exercises under Nasdaq rules.

Negatives

• The company has a going concern warning, with a cash balance of $0.5 million as of June 30, 2026, and a net loss of $4.5 million for the first six months of 2026.
• There is a substantial risk of dilution to existing stockholders due to the conversion of convertible notes, with conversion prices subject to downward adjustments and no stated floor price other than par value.
• The company does not currently have enough authorized shares to cover all potential conversions and warrant exercises, requiring stockholder approval for an increase.
• Previous attempts to increase authorized shares have failed, creating uncertainty about future registration of all issuable shares.
• The company will not receive any proceeds from the resale of shares by selling stockholders.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to low cash balance and operating losses.
• Potential for significant dilution to existing stockholders if the conversion price of the notes is adjusted downward, with no floor price other than par value.
• Insufficient authorized shares to cover all potential conversions and warrant exercises, risking breaches of registration rights obligations.
• Stockholder approval for an increase in authorized shares is required and has been previously denied, creating uncertainty.
• Sales of a substantial number of shares by selling stockholders could depress the market price of the common stock.
• The company may be unable to register remaining shares issuable upon conversion of notes or exercise of warrants if authorized share increase is not approved.

Future Outlook

The company is seeking stockholder approval to increase its authorized share capital to up to 150,000,000 shares. If approved, it intends to file additional registration statements to cover remaining note conversion shares and warrant exercise shares. The company's ability to continue as a going concern is dependent on achieving profitable operations and securing additional financing.

Management Comments

• "We are registering the resale of the Shares covered by this prospectus as required by the registration rights agreements entered into in connection with each of the financings described above."
• "The issuance of the shares of Common Stock covered by this prospectus could cause substantial dilution to our existing stockholders."
• "We do not currently have enough authorized shares of Common Stock to register the full number of shares issuable upon conversion of the Notes and exercise of the Warrants, and our stockholders have previously declined to approve an increase in our authorized shares."
• "If our stockholders do not approve the proposed increase at the Special Meeting, we may be unable to register the remaining shares issuable upon conversion of the Notes or any shares issuable upon exercise of the Warrants, which could put us in breach of our registration rights and other obligations to the Selling Stockholders, and could also leave us unable to satisfy the Notes Reserved Amount covenant..."

Industry Context

StockSavvy.ai notes that NexGel operates in the specialized field of hydrogel manufacturing for medical and cosmetic applications. The company's strategy involves both contract manufacturing and branded consumer products, with a recent acquisition in regenerative biomaterials. The current filing reflects a common scenario for emerging companies needing to raise capital and manage dilution, particularly when seeking to list or expand share availability.

Comparison to Industry Standards

• The company's reliance on convertible notes and warrants for financing is a common practice in the biotechnology and medical device sectors, especially for companies in earlier stages of commercialization or facing financial challenges.
• The 'going concern' warning is a critical indicator, often seen in companies with high R&D costs, long product development cycles, or insufficient revenue to cover operational expenses. Companies like Sorrento Therapeutics or MannKind Corporation have faced similar challenges in the past.
• The dilution risk associated with convertible instruments is a standard concern. Investors in companies like Cassava Sciences or Cassava Sciences have experienced significant dilution from such instruments when share prices decline.
• The need for stockholder approval to increase authorized shares is typical for companies that have issued a significant number of shares or convertible securities, as seen with many small-cap biotech firms seeking to fund clinical trials or acquisitions.

Corporate Governance

Related Party Transactions

• Brian Kieser, a director, personally invested $1,000,000 in the May 2026 Financing.
• Sequence LifeScience, Inc., an entity affiliated with Brian Kieser, invested $5,500,000 in connection with the Celularity transaction.
• Adam Levy, Ian Blackman, Steve Ciardiello, and Steve Glassman (executive officers/directors) hold Notes but have voluntarily excluded their shares from this registration statement.
• Adam Drapczuk (former Interim CFO, current financial consultant) holds Notes but has voluntarily excluded his shares from this registration statement.
• Helena Global Investment Opportunities 1 Ltd. holds the Celularity Note, which was originally to be issued to Celularity Inc.

Stakeholder Impact

• Existing shareholders face significant dilution risk from the conversion of convertible notes, potentially reducing their ownership percentage and per-share value.
• Selling stockholders aim to liquidate their holdings of common stock, which could increase the supply of shares in the market and potentially depress the stock price.
• Creditors and noteholders are subject to the company's ability to meet its obligations, with the 'going concern' warning indicating potential risks to repayment.
• Management and employees holding stock options or restricted stock may see the value of their equity awards impacted by dilution and stock price volatility.

Next Steps

• NexGel will hold a Special Meeting of Stockholders on September 23, 2026, to seek approval for an increase in authorized shares.
• If stockholder approval is obtained, NexGel intends to file additional registration statements or post-effective amendments to register remaining shares issuable upon conversion of notes and exercise of warrants.
• Selling stockholders may sell shares from time to time after the registration statement becomes effective.

Key Dates

Recommendation

The filing presents a mixed picture. While the company is actively managing its financing and acquisition activities, the significant 'going concern' warning, substantial dilution risks from convertible notes, and the critical need for stockholder approval on a previously rejected share increase proposal create considerable uncertainty. The lack of proceeds to the company from this resale further tempers enthusiasm. A 'hold' recommendation reflects the need to observe the outcome of the September 23rd stockholder meeting and the company's ability to navigate its financial challenges before considering a more positive or negative stance.

Keywords

registration statement, convertible notes, stock resale, dilution, going concern, authorized shares, warrants, financing